mjn-neuro, a start-up specialising in neurotechnology applied to digital health and a member of Catalonia.health, and the European pharmaceutical group Neuraxpharm have announced plans to launch EPISERAS®, an innovative digital medical solution designed to enable the early detection of the risk of epileptic seizures in real time.
EPISERAS® is a non-invasive medical device that continuously monitors brain activity through a discreet earbud-shaped sensor. Using advanced artificial intelligence algorithms, the system analyses the brain’s electrical patterns and sends alerts to patients and caregivers minutes before a seizure occurs, when risk levels are high. The solution is aimed at people with drug-resistant epilepsy and seeks to improve safety, autonomy and quality of life in everyday life.
Developed by mjn-neuro, the solution has already been validated and certified in Europe as a Class IIa medical device, with C and UKCA marking. The prospective multicentre clinical study SERAS-Home_RWD is currently underway in Spain, the United Kingdom and Germany, with provisional data being prepared for publication. The launch of EPISERAS® in Europe is planned for the second half of 2026.
According to David Blánquez, CEO and co-founder of mjn-neuro, “Our team has been developing this pioneering project for more than ten years and, thanks to the results obtained in several clinical studies, mjn-neuro has successfully demonstrated solid clinical evidence supporting its effectiveness. We are now focused on ensuring that patients can benefit from this innovation, which will help improve their quality of life and reduce accidents caused by epileptic seizures. Collaborating with Neuraxpharm on the European market launch is a key step in bringing this innovative solution to those who need it most.”
Comments